2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
450
Stomach Neoplasms
295
Rectal Neoplasms
271
Colonic Neoplasms
192
Pancreatic Neoplasms
177
Neoplasm Metastasis
110
Esophageal Neoplasms
88
Neoplasms
68
Carcinoma, Hepatocellular
60
Adenocarcinoma Of Esophagus
47
Cholangiocarcinoma
46
Adenocarcinoma
46
Lymphoma, Large B-Cell, Diffuse
44
Carcinoma, Non-Small-Cell Lung
41
Biliary Tract Neoplasms
38
Gallbladder Neoplasms
31
Gastrointestinal Neoplasms
29
Recurrence
25
Liver Neoplasms
25
Ovarian Neoplasms
23
Esophageal Squamous Cell Carcinoma
23
Breast Neoplasms
22
Peritoneal Neoplasms
18
Bile Duct Neoplasms
17
Unspecified Adult Solid Tumor, Protocol Specific
16
Parkinson Disease 4, Autosomal Dominant Lewy Body
14
Locally Advanced Rectal Cancer
13
Head and Neck Neoplasms
13
Lung Neoplasms
12
Lymphoma, Non-Hodgkin
11
Interventions
trifluridine tipiracil drug combination
1
Trastuzumab
1
Panitumumab
1
Oxaliplatin
1
Nivolumab
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Dihydropyrimidine Dehydrogenase Deficiency
×
Oxaliplatin
×
Clear all
NCT06245356
2025-12-10
TRIFLUOX-DP
UNICANCER
Phase 2
Recruiting
73 enrolled